Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
Farah M. Shurrab,
Duaa W. Al-Sadeq,
Haissam Abou-Saleh,
Nader Al-Dewik,
Amira E. Elsharafi,
Fatima M. Hamaydeh,
Bushra Y. Abo Halawa,
Tala M. Jamaleddin,
Huda M. Abdul Hameed,
Parveen B. Nizamuddin,
Fathima Humaira Amanullah,
Hanin I. Daas,
Laith J. Abu-Raddad,
Gheyath K. Nasrallah
Affiliations
Farah M. Shurrab
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
Duaa W. Al-Sadeq
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
Haissam Abou-Saleh
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
Nader Al-Dewik
Women’s Wellness and Research Center (WWRC), Clinical and Metabolic Genetics Section, Pediatrics Department, Hamad General Hospital (HGH), Interim Translational Research Institute (iTRI), Hamad Medical Corporation (HMC), College of Health and Life Science (CHLS), Hamad Bin Khalifa University (HBKU), Doha P.O. Box 3050, Qatar
Amira E. Elsharafi
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
Fatima M. Hamaydeh
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
Bushra Y. Abo Halawa
Biological Science Program, Department of Biological and Environmental Sciences, College of Arts and Science, Qatar University, Doha P.O. Box 2713, Qatar
Tala M. Jamaleddin
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
Huda M. Abdul Hameed
Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
Parveen B. Nizamuddin
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
Fathima Humaira Amanullah
Biomedical Research Center, Qatar University, Doha P.O. Box 2713, Qatar
Hanin I. Daas
College of Dental Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.
